A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for the Maintenance Treatment of Anemia in Kidney Transplant Recipients.
Condition: AnemiaInterventions: Drug: Darbepoetin alfa; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheCompleted - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2008 Category: Research Source Type: clinical trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Conditions: Anemia; Chronic Kidney Disease; Kidney DiseaseInterventions: Drug: darbepoetin alfa QW; Drug: darbepoetin alfa Q2WSponsor: AmgenTerminated - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2007 Category: Research Source Type: clinical trials
